Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Smoldering Multiple Myeloma: early-phase trial registry
8 of 21 indexed Smoldering Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 8 currently recruiting · #797 of 28,707 conditions by registered trial count
Smoldering Multiple Myeloma: 21 US clinical trials tracked, 8 recruiting.
Smoldering Multiple Myeloma is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 6 of these trials.
Enrollment posture brief
Registry condition smoldering-multiple-myeloma
OPEN 8 | RECR 38% | LATE 3 | EARLY 9 | RANK #797 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Behavior, Health (38% recruiting · 21 trials)
Smoldering Multiple Myeloma lists 8 open slots (38% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Smoldering Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Smoldering Multiple Myeloma recruits in line with its size-band peers.
8 of 21 indexed trials (38.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Smoldering Multiple Myeloma research.
Dana-Farber Cancer Institute accounts for 6 of 21 trials (28.6%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Smoldering Multiple Myeloma enrolment sits around 100 participants.
Median target enrolment is 100 among the 21 trials that report a genuine target (sentinel values excluded). 10 of those (47.6%) plan for fewer than 100 participants.
-
Smoldering Multiple Myeloma research is mostly interventional.
15 interventional and 6 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
NCT02269592
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
NCT03717844
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
University of Miami
NCT05361694
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Tufts Medical Center
NCT06365060
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
NCT05640843
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
University of Utah
NCT06212323
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Irene Ghobrial, MD
NCT05469893
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
NCT05597345
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
NCT01177527
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
National Cancer Institute (NCI)
NCT00114101
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development
NCT03301220
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
NCT01169337
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Case Comprehensive Cancer Center
NCT05831358
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
International Myeloma Foundation
NCT03289299
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
NCT04850846
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
NCT03236428
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
NCT04920084
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
NCT05767359
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Massachusetts General Hospital
NCT02886065
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
NCT02916771
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Innate Pharma
NCT01222286
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Smoldering Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Smoldering Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Smoldering Multiple Myeloma page
21 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Smoldering Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Smoldering Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Smoldering Multiple Myeloma condition card totals 21 registered trials; most-linked intervention Lenalidomide; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.